1Department of Hematology and Oncology, Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
2Oncology Clinical Trials Support Unit, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan
3Department of Pharmacy, University of Michigan, Ann Arbor, Michigan
*Correspondence: University of Michigan, 1500 E. Medical Center Dr., C369 Med Inn Building, SPC 5848, Ann Arbor, Michigan 48109 telephone: 734-615-1623; [email protected]
Submitted June 10, 2022; accepted August 31, 2022; published November 1, 2022.
Disclosure: Dr Daignault-Newton is on the Statistician Board of The Journal of Urology®.
Support: This work was supported by Celgene/Bristol-Myers Squibb.
Conflict of Interest: Ajjai Alva has served in an advisory role to AstraZeneca, Merck, Pfizer, Bristol-Myers Squibb; received research funding through the institution from Genentech, Bristol-Myers Squibb, Merck Sharp & Dohme, Prometheus Laboratories, Mirati Therapeutics, AstraZeneca, Roche, Bayer, Progenics, Astellas Pharma, Arcus Biosciences, Celgene, Janssen; received Travel, Accommodations, Expenses from Merck and Bristol-Myers Squibb. Phillip Palmbos has received research funding through Roche and Immunomedics. Zachery R. Reichert has served in an advisory role to Dendreon; received research funding through the institution from AstraZeneca. Ulka Vaishampayan has served in an advisory role to Pfizer, Exelixis, Bayer, Bristol-Myers Squibb/Medarex, Merck Serono, Advanced Accelerator Applications, Alkermes, Helsinn Therapeutics; received research funding through Astellas Pharma, Exelixis, Bristol-Myers Squibb, Merck KGaA; participated in a speaker’s bureau for Pfizer, Bayer, Exelixis. David C. Smith has received research funding through the institution from Agensys, Incyte, Lilly, Novartis, Seattle Genetics, Bristol-Myers Squibb/Medarex, Genentech, Astellas Pharma, Bayer, ESSA, Roche, MedImmune. All remaining Authors have declared no conflicts of interest.
Ethics Statement: This study protocol was approved by the University of Michigan Institutional Review Board (IRB No. HUM00135166) and conducted in accordance with the Declaration of Helsinki.
